SOUTH
PLAINFIELD, N.J., Nov. 3, 2023
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today
announced that on Nov. 1, 2023, the
company approved non-statutory stock options to purchase an
aggregate of 14,005 shares of its common stock and 19,125
restricted stock units ("RSUs"), each representing the right to
receive one share of its common stock upon vesting, to 21 new
employees. The awards were made pursuant to the
Nasdaq inducement grant exception as a component of the new
hires' employment compensation.
The inducement grants were approved by PTC's Compensation
Committee on Nov. 1, 2023, and are
being made as an inducement material to each employee's acceptance
of employment with the company in accordance with
Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of $18.45
per share, the closing price of PTC's common stock on Nov. 1,
2023, the date of the grant. The stock options each have a 10-year
term and vest over four years, with 25% of the original number of
shares vesting on the first anniversary of the applicable
employee's new hire date and 6.25% of the original number of shares
vesting at the end of each subsequent three-month period thereafter
until fully vested, subject to the employee's continued service
with the company through the applicable vesting dates. The RSUs
each will vest over four years with 25% of the original number of
shares vesting on each annual anniversary of the applicable
employee's new hire date until fully vested, subject to the
employee's continued service with the company through the
applicable vesting dates.
ABOUT PTC THERAPEUTICS, INC.
PTC is a science-driven,
global biopharmaceutical company focused on the discovery,
development and commercialization of clinically differentiated
medicines that provide benefits to patients with rare disorders.
PTC's ability to innovate to identify new therapies and to globally
commercialize products is the foundation that drives investment in
a robust and diversified pipeline of transformative medicines.
PTC's mission is to provide access to best-in-class treatments for
patients who have little to no treatment options. PTC's strategy is
to leverage its strong scientific and clinical expertise and global
commercial infrastructure to bring therapies to patients. PTC
believes this allows it to maximize value for all its stakeholders.
To learn more about PTC, please visit us at www.ptcbio.com and
follow us on Instagram, Facebook, Twitter, and LinkedIn.
For more information please contact:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original
content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-301977135.html
SOURCE PTC Therapeutics, Inc.